

QHerit® | QNatal® Advanced

Carrier
Screening

Noninvasive Prenatal
Screening

Quest Diagnostics® is your comprehensive prenatal genetic screening and diagnostic resource

Providing easy-to-read results so you can help patients make informed decisions throughout every step of their journey.



QHerit® Carrier Screening

For patients either considering pregnancy or already pregnant, a pan-ethnic panel developed with ACOG and ACMG recommendations in mind. Ideal to determine carrier risks of inherited genetic diseases.

Starts with a simple blood draw

Clinically relevant results that harness the power of next-generation sequencing and a robust, ever-growing genomics database

The **No Surprise** patient assistance program determines prior authorization requirements and insurance coverage



QNatal® Advanced Noninvasive Prenatal Screening

For pregnant patients, a noninvasive cfDNA prenatal screen that can help identify the most common fetal aneuploidies.* In addition, if elected, QNatal Advanced can screen for sex chromosome abnormalities and certain microdeletions.

Simple maternal blood draw performed as early as 10 weeks into the pregnancy

High sensitivity and specificity** with results reported in a concise, easy-to-read report

The interactive Cost Estimator provides an estimated out-of-pocket responsibility in real time, to give patients an idea of what they might owe



Patients have access to their estimation at MyNIPTCost.com



Learn more at QHerit.com



Learn more at QNatal.com

Supporting you and your patients throughout the pregnancy journey



Flexible financial and support options

- In-network status with the majority of health plans nationwide
- Supplemental financial assistance program for both insured and uninsured patients

QHerit additional financial support

81% of insured patients pay less than \$25^a

- QHerit No Surprise program helps determine prior authorization requirements and limits patients' out-of-pocket responsibility to \$300

QNatal Advanced additional financial support^b

79% of patients pay less than \$99^c

- If the health plan denies QNatal Advanced as a "noncovered service," the patient should pay no more than \$300
- Easy to use, interactive Cost Estimator to provide patients an idea of potential out-of-pocket responsibility. Patients may access their estimation at MyNIPTCost.com

Patient Navigators

Women's health billing professionals who work directly with patients to answer questions about QNatal Advanced noninvasive prenatal screening or QHerit carrier screening.



Review patient's insurance coverage



Clarify costs and answer billing questions



Call **1.888.445.5011** or email PatientNavigators@QuestDiagnostics.com



A leader in genetic testing

- Specialized, innovative solutions and reliable insights that help you and your patients make informed decisions
- Clinical and diagnostic testing experts who can provide answers and share expertise
- Genomic Science Specialists available for test selection and result interpretation support for clinicians, and for post-test consultation support for patients. **Call 1.866.GENE.INFO (1.866.436.3463)**



For resources and support on prenatal genetic screening, visit QuestDiagnostics.com/OBGYN or call **1.844.QUESTOB (1.844.783.7862)**

^a Based on Quest Diagnostics 2023 fiscal year claims analysis.

^b Alternative UPP pricing is available in Florida, New Hampshire, Massachusetts, Maine, Rhode Island, Vermont, and Texas. Insured patients whose plan denied QNatal Advanced as a "noncovered service" should not pay more than \$300.

^c Based on Quest Diagnostics 2022 fiscal year claims analysis.

Important Information

*QNatal[®] Advanced is a cell-free DNA test that screens for increased risk of certain fetal chromosomal abnormalities that may cause birth defects, including Trisomy 21 (Down Syndrome), Trisomy 18, Trisomy 13, and certain sex chromosome abnormalities (ie, 45,X; 47,XXY; 47,XXX; and 47,XYY). In addition, if selected as an option, QNatal Advanced can screen for certain microdeletions (ie, 22q, 5p, 1p36, 15q, 11q, 8q, and 4p) that may cause birth defects, and/or for fetal sex. This test does not assess the risk of fetal anomalies such as neural tube defects or ventral wall defects. QNatal Advanced is not recommended before 10 weeks gestation due to a significantly increased risk of a failed result. QNatal Advanced is a laboratory-developed test that has been developed and validated pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA), and as such it has not been reviewed by FDA.

QNatal is a "screening" test, not a diagnostic test, and therefore all positive/increased risk results should be followed by genetic counseling and further diagnostic testing and procedures, when clinically indicated. Pregnancy management decisions should not be based on the results of a cfDNA test alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic marker and may be lower for rare conditions. Performance data for QNatal Advanced may be obtained by contacting Quest Diagnostics at 1.866.GENE.INFO (1.866.436.3463).

**QHerit[®], QHerit Plus, QHerit Extended, QHerit 421, QHerit 381, QHerit 445, and QHerit 400 are carrier "screening" tests, and they screen for variations in genes linked to certain health disorders that can be passed from parents to children. QHerit screens 24 genes; QHerit Plus screens 85 genes; QHerit Extended screens 150 genes; QHerit 421 screens 421 genes; QHerit 381 screens 381 genes; QHerit 445 screens 445 genes; and QHerit 400 screens 400 genes. For a full list of genes for which each panel in the QHerit family screens, visit QHerit.com. If the results from any panel in the QHerit family suggest a patient may be a carrier of a gene variation that can cause a health disorder in offspring, it is recommended that the reproductive partner be offered genetic screening and genetic counseling be provided for both partners. Pregnancy management decisions should not be based on the results of these screening tests alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic variation and may be lower for rare conditions. Patients should discuss with their provider reproductive implications and the need for further testing based on screening results. Each panel in the QHerit family is a laboratory-developed test that has been developed and validated pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA) and, as such, has not been reviewed by the FDA.

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest[®], Quest Diagnostics[®], any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—[®] and [™]—are the property of their respective owners. © 2023-2024 Quest Diagnostics Incorporated. All rights reserved. SB12942 5/2024